No abstract available
Keywords:
atherosclerosis; canakinumab; evolocumab; mortality; prevention and control; randomized controlled trials as topic.
MeSH terms
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / therapeutic use*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Atherosclerosis / blood
-
Atherosclerosis / diagnosis
-
Atherosclerosis / drug therapy*
-
Atherosclerosis / mortality
-
Biomarkers / blood
-
C-Reactive Protein / metabolism
-
Cause of Death
-
Cholesterol, LDL / blood
-
Down-Regulation
-
Drug Therapy, Combination
-
Dyslipidemias / blood
-
Dyslipidemias / diagnosis
-
Dyslipidemias / drug therapy*
-
Dyslipidemias / mortality
-
Evidence-Based Medicine
-
Humans
-
Hypolipidemic Agents / adverse effects
-
Hypolipidemic Agents / therapeutic use*
-
Inflammation Mediators / blood
-
Myocardial Ischemia / blood
-
Myocardial Ischemia / diagnosis
-
Myocardial Ischemia / mortality
-
Myocardial Ischemia / prevention & control*
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Stroke / blood
-
Stroke / diagnosis
-
Stroke / mortality
-
Stroke / prevention & control*
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Biomarkers
-
Cholesterol, LDL
-
Hypolipidemic Agents
-
Inflammation Mediators
-
canakinumab
-
C-Reactive Protein
-
evolocumab